Raimonda Kubiliūtė1,2, Kristina Žukauskaitė1,2, Algirdas Žalimas1,2, Albertas Ulys2, Rasa Sabaliauskaitė2, Arnas Bakavičius2,3, Arūnas Želvys3,4, Feliksas Jankevičius3,4, Sonata Jarmalaitė5,6. 1. Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania. 2. National Cancer Institute, Santariskiu 1, LT‑08406, Vilnius, Lithuania. 3. Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. 4. Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. 5. Institute of Biosciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania. sonata.jarmalaite@nvi.lt. 6. National Cancer Institute, Santariskiu 1, LT‑08406, Vilnius, Lithuania. sonata.jarmalaite@nvi.lt.
Abstract
OBJECTIVE: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumor characterized by the highest mortality rate of the genitourinary cancers, and, therefore, new diagnostic and/or prognostic biomarkers are urgently needed. METHODS: Based on genome-wide DNA methylation profiling in 11 pairs of ccRCC and non-cancerous renal tissues (NRT), the methylation at regulatory regions of ZNF677, FBN2, PCDH8, TFAP2B, TAC1, and FLRT2 was analyzed in 168 renal tissues and 307 urine samples using qualitative and quantitative methylation-specific PCR (MSP). RESULTS: Significantly higher methylation frequencies for all genes were found in ccRCC tissues compared to NRT (33-60% vs. 0-11%). The best diagnostic performance demonstrated a panel of ZNF677, FBN2, PCDH8, TFAP2B & TAC1 with 82% sensitivity and 96% specificity. Hypermethylation of ZNF677 and PCDH8 in the tissue samples was significantly related to numerous adverse clinicopathologic parameters. For the urine-based ccRCC detection, the highest diagnostic power (AUC = 0.78) was observed for a panel of ZNF677 & PCDH8 (with or without FBN2 or FLRT2) with 69-78% sensitivity and 69-80% specificity, albeit with lower values in the validation cohort. Besides, methylation of PCDH8 was significantly related to higher tumor stage and fat invasion in the study and validation cohorts. Moreover, PCDH8 was strongly predictive for OS (HR, 5.7; 95% CI 1.16-28.12), and its prognostic power considerably increased in combination with ZNF677 (HR, 12.5; 95% CI 1.47-105.58). CONCLUSION: In summary, our study revealed novel, potentially promising DNA methylation biomarkers of ccRCC with the possibility to be applied for non-invasive urine-based ccRCC detection and follow-up.
OBJECTIVE: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumor characterized by the highest mortality rate of the genitourinary cancers, and, therefore, new diagnostic and/or prognostic biomarkers are urgently needed. METHODS: Based on genome-wide DNA methylation profiling in 11 pairs of ccRCC and non-cancerous renal tissues (NRT), the methylation at regulatory regions of ZNF677, FBN2, PCDH8, TFAP2B, TAC1, and FLRT2 was analyzed in 168 renal tissues and 307 urine samples using qualitative and quantitative methylation-specific PCR (MSP). RESULTS: Significantly higher methylation frequencies for all genes were found in ccRCC tissues compared to NRT (33-60% vs. 0-11%). The best diagnostic performance demonstrated a panel of ZNF677, FBN2, PCDH8, TFAP2B & TAC1 with 82% sensitivity and 96% specificity. Hypermethylation of ZNF677 and PCDH8 in the tissue samples was significantly related to numerous adverse clinicopathologic parameters. For the urine-based ccRCC detection, the highest diagnostic power (AUC = 0.78) was observed for a panel of ZNF677 & PCDH8 (with or without FBN2 or FLRT2) with 69-78% sensitivity and 69-80% specificity, albeit with lower values in the validation cohort. Besides, methylation of PCDH8 was significantly related to higher tumor stage and fat invasion in the study and validation cohorts. Moreover, PCDH8 was strongly predictive for OS (HR, 5.7; 95% CI 1.16-28.12), and its prognostic power considerably increased in combination with ZNF677 (HR, 12.5; 95% CI 1.47-105.58). CONCLUSION: In summary, our study revealed novel, potentially promising DNA methylation biomarkers of ccRCC with the possibility to be applied for non-invasive urine-based ccRCC detection and follow-up.
Authors: Vera L Costa; Rui Henrique; Stine Aske Danielsen; Mette Eknaes; Patrícia Patrício; António Morais; Jorge Oliveira; Ragnhild A Lothe; Manuel R Teixeira; Guro E Lind; Carmen Jerónimo Journal: Epigenetics Date: 2011-09-01 Impact factor: 4.528
Authors: Jens Bedke; Stephan Buse; Maria Pritsch; Stephan Macher-Goeppinger; Peter Schirmacher; Axel Haferkamp; Markus Hohenfellner Journal: BJU Int Date: 2008-12-08 Impact factor: 5.588
Authors: Cristina Battagli; Robert G Uzzo; Essel Dulaimi; Inmaculada Ibanez de Caceres; Rachel Krassenstein; Tahseen Al-Saleem; Richard E Greenberg; Paul Cairns Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo Journal: Eur Urol Date: 2018-09-19 Impact factor: 20.096
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen Journal: BMJ Date: 2015-10-28